Next-generation medicine design is no longer about small molecule enzyme inhibitors only! Traditional targets and modalities that have provided rich substrates for drug design and decades of productive industrial and academic research are not the primary targets of the future. There is a slow but steady shift in the target landscape. Novel modalities such as "biased signaling" of GPCRs, covalent kinase inhibitors, allosteric kinase "activators", ion-channel modulators, protein-protein interaction disruptors, protein degraders and gene therapy are areas of intense scientific research.

The 2017 CADD Gordon Conference will focus on next generation computer-aided medicine design as envisioned from a biotech/pharmaceutical industry vantage point. The program is designed to celebrate success stories, share and learn from various project teams' trials and tribulations, emphasize opportunities and challenges in the near future.

The conference will bring together top-class international industrial CADD'ers, researchers and academics. In the spirit of the GRC, every talk in the program will have an element of unpublished work. The program will start with two external perspective presentations highlighting the design and development of novel medicines using case studies and will close with two keynote lectures summarizing progress and providing an outlook in two different areas in the field.

We strongly encourage attendees to submit poster presentations as, historically, a handful of posters have been selected for a rapid-fire, TED-like poster talks. Further posters have been an essential part of the GRC program that generates discussion and interaction among the conference attendees.

The 2017 CADD GRC will continue the tradition of outstanding science presented in a relaxed atmosphere infused with a variety of social activities. As we look forward to another outstanding conference in 2017, we welcome your application. Thank you for your interest in the CADD GRC.